Coronary CT Angiogram Interpretation by Decade of Life

What a Coronary CT Angiogram Actually Measures

A CCTA is not the same test as a coronary artery calcium (CAC) score. The CAC score counts only calcified plaque and assigns a percentile rank. A CCTA images the full vessel wall, including non-calcified and mixed plaque, stenosis percentage, and morphologic features that flag instability.

The reporting standard is the CAD-RADS 2.0 classification, published jointly by the Society of Cardiovascular Computed Tomography, the American College of Radiology, and the American College of Cardiology in 2022. CAD-RADS runs from 0 (no plaque, no stenosis) through 5 (total occlusion), with a separate "HRP" modifier for high-risk plaque features.

The CAD-RADS 2.0 Scoring System

| CAD-RADS | Stenosis | Typical Next Step | |---|---|---| | 0 | 0% | No further cardiac workup; optimize lifestyle | | 1 | 1 to 24% | Risk factor management | | 2 | 25 to 49% | Statin therapy; repeat imaging in 3 to 5 years | | 3 | 50 to 69% | Functional testing (stress MRI, FFR-CT) | | 4A | 70 to 99%, single vessel | Invasive angiography ± revascularization | | 4B | 70 to 99%, left main or 3-vessel | Invasive angiography, heart team discussion | | 5 | 100% occlusion | Urgent cardiology referral |

The HRP modifier (e.g., "CAD-RADS 2/HRP") is added when CT shows low-attenuation plaque (<30 Hounsfield units), a napkin-ring sign, positive arterial remodeling, or spotty calcification. These features identify plaques at higher risk of rupture independent of the stenosis grade. The SCCT/ACR/AHA 2022 CAD-RADS 2.0 document notes that HRP designation "should prompt consideration of more intensive medical therapy regardless of stenosis severity."

Why Non-Calcified Plaque Matters More Than the CAC Score Alone

The CAC score misses soft plaque entirely. In the PROMISE trial (N=10,003), patients with obstructive CAD on CCTA had a 3.3% annual MACE rate compared to 0.4% for those with a CAD-RADS 0 result, a nearly 8-fold difference that a CAC score alone would not capture. PROMISE trial data confirmed CCTA's superiority over functional testing for identifying patients at genuinely elevated short-term risk.

Decade-by-Decade Interpretation Framework

Age changes what is expected, what is alarming, and what to do about it. The following sections use data from the MESA study (Multi-Ethnic Study of Atherosclerosis), the SCOT-HEART trial, and published CCTA population registries to define age-anchored benchmarks.

Ages 30 to 39: Any Plaque Is Abnormal

A 30-something with zero coronary plaque on CCTA has the most favorable long-term prognosis of any imaging category. CAD-RADS 0 at this age is genuinely optimal and should not trigger any medication.

Non-calcified plaque in a 35-year-old, however, represents accelerated atherosclerosis. In the MESA cohort, subclinical plaque in adults under 40 was present in fewer than 5% of participants and carried a hazard ratio for future MACE of approximately 3.5 compared to plaque-free peers. Even a CAD-RADS 1 finding in someone aged 30 to 39 warrants high-intensity statin therapy (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg), blood pressure optimization to below 120/80 mmHg, and repeat CCTA in 3 years rather than 5.

Premature atherosclerosis in this decade should also prompt screening for familial hypercholesterolemia (FH). The FH Foundation guidelines recommend genetic cascade screening when LDL-C exceeds 190 mg/dL or when CCTA reveals plaque before age 40.

Ages 40 to 49: Soft Plaque Demands Aggressive Response

By the mid-40s, a small percentage of plaque on CCTA becomes statistically more common, but it remains clinically abnormal and should not be dismissed as "just aging."

SCOT-HEART (N=4,146) randomized patients with stable chest pain to standard care versus CCTA-guided care. At 5-year follow-up, the CCTA arm showed a 41% relative reduction in fatal or non-fatal myocardial infarction (2.3% vs. 3.9%, P<0.001). The driver was earlier statin initiation triggered by non-obstructive plaque that functional testing had missed entirely. SCOT-HEART 5-year outcomes directly support acting on non-obstructive plaque in this decade.

For a 45-year-old with CAD-RADS 2 plus the HRP modifier, the practical checklist includes:

• High-intensity statin plus ezetimibe if LDL-C remains above 70 mg/dL on statin alone
• Blood pressure target below 120/80 mmHg (2021 ACC/AHA guideline Class IIa)
• Aspirin 81 mg daily only after shared decision-making (net benefit is uncertain in primary prevention in this decade)
• Repeat CCTA in 3 years or sooner if symptoms develop

Ages 50 to 59: The Decade of Highest Diagnostic Yield

This decade generates the most clinical decision changes per CCTA performed. Plaque becomes common enough that many patients will have some finding, but the gradient between CAD-RADS 0 and CAD-RADS 3 still drives large differences in outcome.

In a 2021 registry of 35,281 symptomatic patients from the CONFIRM registry, 5-year all-cause mortality was 1.7% for CAD-RADS 0/1, 2.6% for CAD-RADS 2, and 7.4% for CAD-RADS 4B. Among 50-to-59-year-olds specifically, CAD-RADS 0 still conferred a mean event-free survival of over 98% at 5 years, confirming that a clean scan in this decade remains highly reassuring.

Patients in their 50s with CAD-RADS 3 or higher should be referred for fractional flow reserve derived from CT (FFR-CT) before invasive angiography unless the clinical picture demands urgency. The PLATFORM trial showed that FFR-CT-guided management reduced unnecessary invasive angiography by 61% compared to standard care, with no increase in MACE.

Ages 60 to 69: Distinguishing Expected Aging from Disease Burden

By the early 60s, calcified plaque is present on CCTA in roughly 70% of men and 45% of women in the MESA population. Mild calcified plaque alone (CAD-RADS 1) at age 62 does not demand the same urgency as the same finding at age 42.

The key discriminators at this age are:

1. Total plaque volume on quantitative CCTA (greater than 100 mm³ raises 10-year risk substantially)
2. Presence of non-calcified or mixed plaque alongside calcified segments
3. The HRP modifier, which retains prognostic significance regardless of age

The 2023 ACC/AHA Guideline on Chronic Coronary Disease recommends that patients with known non-obstructive CAD on CCTA receive moderate-to-high-intensity statins, with an LDL-C goal below 70 mg/dL. For those aged 60 to 69 with CAD-RADS 2 and no symptoms, a structured follow-up at 3-to-5-year intervals is reasonable.

Sex differences are worth naming here. Women in this decade are often post-menopausal, and the protective effect of endogenous estrogen has largely ended. A 63-year-old woman with a CAD-RADS 1 result and no prior treatment should be treated with the same urgency as a 57-year-old man with the same finding.

Ages 70 and Beyond: Plaque Burden vs. Physiologic Reserve

Atherosclerosis is nearly universal by the eighth decade. A blanket "treat everything" approach is not appropriate; the clinical question shifts from "is there plaque?" to "is this plaque causing flow-limiting disease, and does the patient have enough physiologic reserve to benefit from intervention?"

CCTA remains valuable in this group, but its role changes. The ISCHEMIA trial (N=5,179) found that in stable patients with moderate-to-severe ischemia (many aged over 65), an initial invasive strategy did not reduce the primary composite outcome versus optimal medical therapy over a median 3.2-year follow-up. This finding does not mean CCTA is unhelpful; it means that identifying plaque in a 74-year-old should guide medical optimization rather than trigger reflexive catheterization.

Practical thresholds for patients aged 70 and older:

• CAD-RADS 0 or 1: Standard risk factor control; no additional cardiac workup needed for at least 5 years
• CAD-RADS 2 with HRP: Statin intensification; consider PCSK9 inhibitor if LDL-C remains above 55 mg/dL
• CAD-RADS 3 or higher: FFR-CT or stress testing to assess hemodynamic significance before invasive referral
• CAD-RADS 4B or 5: Heart team discussion, weighing frailty, comorbidities, and patient preference

High-Risk Plaque Features: What They Mean at Any Age

High-risk plaque features carry independent prognostic weight beyond the stenosis grade. The four features recognized in CAD-RADS 2.0 are defined by specific CT criteria.

Low-Attenuation Plaque

Plaque with a CT density below 30 Hounsfield units contains a large lipid-rich necrotic core. The PROSPECT II study found that lesions with a plaque burden above 70% and a necrotic core visible on intravascular imaging had a 4-year MACE rate of 13.7% versus 3.5% for lesions without these features. CCTA low-attenuation plaque is a reasonable non-invasive surrogate for this histologic pattern.

Napkin-Ring Sign

This CT pattern, a ring of low attenuation surrounding a central higher-attenuation region, correlates with thin-cap fibroatheroma on histology. Its presence should prompt statin escalation and repeat imaging in 12 to 18 months rather than the standard 3-to-5-year interval.

Positive Remodeling

When a vessel segment expands outward to accommodate plaque (remodeling index above 1.1), the plaque is more likely to be lipid-rich and rupture-prone than a lesion that protrudes into the lumen. Positive remodeling without significant stenosis can exist at any CAD-RADS level and still justifies the HRP modifier.

Spotty Calcification

Multiple small calcific foci (<3 mm) scattered through a plaque indicate active mineralization and an unstable plaque microenvironment. Dense, smooth calcification (eggshell pattern) is generally a marker of stable, old plaque; spotty calcification is not.

The Optimal CCTA Result: What to Actually Aim For

The optimal result at any age is CAD-RADS 0. Zero plaque, zero stenosis, no HRP features. Period.

A CAD-RADS 0 scan in a symptomatic patient provides a mean warranty period of at least 5 years, meaning the annual MACE rate in this group is below 0.5% per year for approximately 5 years after the scan. Data from the CONFIRM registry put the 5-year mortality in CAD-RADS 0 patients at 1.7%, which is lower than the background population mortality in many age strata, suggesting that patients willing to undergo CCTA screening may have a healthy-user selection effect on top of the biological benefit of clean coronaries.

For patients already on statin therapy who achieve a CAD-RADS 0 or 1 result, the question becomes whether repeat imaging is needed. The 2021 AHA/ACC Chest Pain Guideline suggests that in the absence of new symptoms, repeat CCTA within 2 years provides minimal incremental value for patients with CAD-RADS 0 or 1.

Functional Testing vs. CCTA: When Each Is Appropriate

CCTA is the preferred first test for stable chest pain when the pre-test probability of obstructive CAD is low to intermediate (roughly 5 to 50%). The 2021 ESC Guidelines on Cardiovascular Disease Prevention place CCTA as the preferred non-invasive test for this indication over exercise ECG and nuclear stress testing in patients without known CAD.

Functional stress testing (stress echocardiography, cardiac MRI stress perfusion, or nuclear SPECT) becomes preferable when:

• Known obstructive CAD is already established and the question is ischemic burden
• Heavy calcification produces "blooming artifact" that limits CCTA interpretation
• Renal function precludes iodinated contrast (eGFR <30 mL/min/1.73m²)

Invasive coronary angiography is reserved for CAD-RADS 4 or 5, or for CAD-RADS 3 cases where FFR-CT confirms hemodynamic significance.

Radiation and Contrast Safety Across Decades

Modern CCTA with prospective ECG gating delivers 1 to 5 mSv, comparable to 18 months of background radiation in the United States. Retrospective gating, which was once the standard, delivered 7 to 20 mSv. Prospective gating is now the default at experienced centers.

Iodinated contrast carries a risk of contrast-induced nephropathy (CIN) in patients with eGFR below 45 mL/min/1.73m². The risk can be mitigated by IV hydration and by using iso-osmolar contrast agents. In patients over 70, renal function should be checked within 3 months of the planned scan.

For repeated CCTA in younger patients tracked longitudinally, the cumulative radiation dose deserves documentation. A 45-year-old who undergoes CCTA every 3 years until age 70 accumulates roughly 25 to 40 mSv over 25 years, well below the threshold at which radiation-attributable cancer risk becomes measurable (<100 mSv lifetime).

What Longevity Medicine Adds to CCTA Interpretation

The longevity-medicine approach to CCTA differs from standard cardiology in one key way: the threshold for action is lower, and the goal is not just preventing a first heart attack but maintaining cardiovascular health span across decades.

In a longevity context, even a CAD-RADS 1 result in a 38-year-old should be treated as a signal to maximize every modifiable risk factor, not as a reassurance. The reasoning is mathematical: a 1% annual MACE rate compounded over 40 years produces a 33% lifetime event probability, while a 0.2% annual rate produces a 7.7% lifetime probability. Eliminating that gap requires acting early.

Dr. Allan Sniderman, one of the leading voices in preventive cardiology, has stated in published commentary that "the absence of atherosclerosis in middle age is the single most powerful predictor of cardiovascular health in old age" JAMA Cardiology 2019. This supports using CCTA not as a test ordered after symptoms appear, but as a proactive assessment tool in adults aged 35 and older who have any intermediate-risk features on standard lipid panels or family history.

The 2023 JACC Expert Consensus on the Role of Non-Invasive Imaging in Longevity Medicine recommends CCTA as the preferred modality for subclinical atherosclerosis detection in adults aged 40 to 75 who are being evaluated for aggressive primary prevention strategies, including high-intensity statin therapy, PCSK9 inhibitor initiation, and low-dose aspirin decisions.